Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able and willing to give written informed consent and comply with the requirements of the study protocol~* Negative serum pregnancy test (for women of child bearing age)~* Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months (1 year) after completion of treatment.~* IgG \& IgM levels within normal limits~* Adequate renal function as indicated by serum creatinine measurements.~* No previous biological use (investigational or approved) except for the three approved anti-TNF alpha therapies~* Patients who have been treated with anti-TNF alpha therapies must be off of infliximab and adalimumab for two months before study entry and off of etanercept for one month before study entry~* No use of phosphodiesterase type 5 inhibitors (PDE5) (i.e. Sildenafil, Tadalafil, and Vardenafil) 1 week prior to the study and during the course of the study.~* SBP ≤ 140/90 for two months prior to study enrollment~Exclusion Criteria:~* Prior history of MI, CVA, CABG, PTCA, or peripheral vascular disease~* Any serious concomitant medical condition that could interfere with the study.~* Patients with insulin dependent diabetes~* Failure to provide written consent.~* Individuals with HIV infections~* SBP \> 140/90 at two months prior to study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituxan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).